Compare Amgen, Inc. (AMGN) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Amgen, Inc. trades at $357 (market cap $196.12B), while Global X NASDAQ 100 Covered Call ETF trades at $18.21. The key difference: Amgen, Inc. pays a 2.77% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | QYLD | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $388.16 | $18.52 |
52-Week Low | $271.18 | $16.46 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
QYLD trades at $18.46, up 0.38% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's strategy of selling covered calls on the Nasdaq-100 provides high monthly dividends, but long-term performance has lagged the index's growth. Recent news highlights concerns over NAV erosion despite the 12% yield.
The outlook for QYLD is mixed: it offers high income for retirees but faces structural headwinds in bull markets due to capped upside. Risks include underperformance versus the Nasdaq-100 and reliance on options premiums. Investors seeking steady cash flow may find value, but total return potential remains constrained.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
